Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature

• Overall prognosis of uterine leiomyosarcoma (ULMS) is poor with a low 5-year survival rate. • Microsatellite instability (MSI)-high ULMS is not well documented in current literature. • Immune checkpoint inhibitors such as pembrolizumab have been shown to have good efficacy in treating MSI-high sol...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gynecol Oncol Rep
Autors principals: Wang, Yannan J., Williams, Heather R., Brzezinska, Bogna N., Gaidis, Anna, Patel, Bhavi, Munroe, Janet, White, Joseph, Rungruang, Bunja
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2021
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843391/
https://ncbi.nlm.nih.gov/pubmed/33537390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2021.100701
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars